ExeVir, a spin out of VIB, is a biotech company that is developing single domain antibody therapies providing broad protection against viral infections.
ExeVir is harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses.
ExeVir was founded in 2020 by Xavier Saelens and Nico Callewaert. The company is headquartered in Ghent, Flemish Region, Belgium.
ExeVir Bio is using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat.
ExeVir's lead compound, an enhanced variant of VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell.
ExeVir also plans to develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.
ExeVir has closed its Series A funding raising a total of €42M ($50M) on Mar 16, 2021. The latest financing was led by Fund+ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, with participations from SRIW, Noshaq, Vives IUF and others.